Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Sanofi announces that it has successfully priced its offering of EUR 1.5 billion of notes across 2 tranches: • €850 million floating rate notes, due March 2027, bearing interest at 3-month Euribor ...

Global commodity trader Cargill plans to add 500 jobs to its global capability centres (GCCs) in the next two to three years, ...

William Pao, former Roche R&D leader and Pfizer CDO, now leads Revelio Therapeutics (formerly Launchpad) as CEO, joins ...

Flovie Martins joins Ujjivan Small Finance Bank as head of corporate communications. Prior to this, Martins was working with ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction with bortezomib, lenalidomide and dexamethasone (VRd) to treat ...

Earlier in her career, she was an Associate Principal at McKinsey & Company ... Prior to his time at Intercept, Mr. Durso spent over two decades at Sanofi, where he held multiple senior leadership ...

Gain valuable work experience at companies or organizations in your career field, Work in one of NYC’s cornerstone industries, Meet students from all over CUNY with similar interests as you, And earn ...

Global investment firm CD&R on Monday announced an open offer to acquire a 26 per cent stake in Sanofi Consumer Healthcare India Ltd for an aggregate of up to Rs 2,983 crore. The development follows ...

The Bpifrance stake is part of a guarantee from the French Government to keep jobs and production in the country. Sanofi honing its focus on innovative medicines and vaccines while shedding its ...